Gilead Sciences (GS-6637) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Gilead Sciences (GS-6637) General Information

Description

Phase-2 ready compound utilizing a novel pathway for the treatment of addiction. The compound is a inhibitor that modifies dopaminergic tone by preventing pathophysiologic dopamine surges and associated craving without changes to basal dopamine.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 333 Lakeside Drive
  • Foster City, CA 94404
  • United States
Primary Industry
Buildings and Property
Other Industries
Biotechnology
Drug Discovery
Corporate Office
  • 333 Lakeside Drive
  • Foster City, CA 94404
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gilead Sciences (GS-6637) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Gilead Sciences (GS-6637)‘s full profile, request access.

Request a free trial

Gilead Sciences (GS-6637) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Gilead Sciences (GS-6637)‘s full profile, request access.

Request a free trial

Gilead Sciences (GS-6637) FAQs

  • Where is Gilead Sciences (GS-6637) headquartered?

    Gilead Sciences (GS-6637) is headquartered in Foster City, CA.

  • What industry is Gilead Sciences (GS-6637) in?

    Gilead Sciences (GS-6637)’s primary industry is Buildings and Property.

  • Is Gilead Sciences (GS-6637) a private or public company?

    Gilead Sciences (GS-6637) is a Private company.

  • What is Gilead Sciences (GS-6637)’s current revenue?

    The current revenue for Gilead Sciences (GS-6637) is .

  • Who are Gilead Sciences (GS-6637)’s investors?

    Gilead has invested in Gilead Sciences (GS-6637).

  • When was Gilead Sciences (GS-6637) acquired?

    Gilead Sciences (GS-6637) was acquired on 16-Feb-2017.

  • Who acquired Gilead Sciences (GS-6637)?

    Gilead Sciences (GS-6637) was acquired by Amygdala Neurosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process